{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T04:03:15Z","timestamp":1727668995647},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,28]]},"DOI":"10.7759\/cureus.70401","type":"journal-article","created":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T03:29:43Z","timestamp":1727580583000},"source":"Crossref","is-referenced-by-count":0,"title":["Gilteritinib-Induced Hypopituitarism: A Case Report"],"prefix":"10.7759","author":[{"given":"Yuri","family":"Hori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Torimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1254","article-title":"Pharmacological and clinical profile of gilteritinib (Xospata\u00ae tablets 40 mg), a therapeutic agent for relapsed or refractory FLT3-mutated acute myeloid leukemia","volume":"156","author":"Mori M","year":"2021","unstructured":"Mori M, Hidaka K. Pharmacological and clinical profile of gilteritinib (Xospata\u00ae tablets 40 mg), a therapeutic agent for relapsed or refractory FLT3-mutated acute myeloid leukemia. Folia Pharmacol Jpn. 2021, 156:37-46. 10.1254","journal-title":"Folia Pharmacol Jpn"},{"key":"ref2","unstructured":"Zospata Tablets 40 mg Drug Interview HomeRevised. (2023). Accessed. June 10, 2024: https:\/\/amn.astellas.jp\/common\/pdfviewer.html\/content\/dam\/jp\/amn\/jp\/ja\/di\/doc\/Pdfs\/DocNo202311694_y.pdf."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.20050","article-title":"Pharmacological and clinical profile of gilteritinib (Xospata(\u00ae) tablets 40\u2005mg), a therapeutic agent for relapsed or refractory FLT3-mutated acute myeloid leukemia (Article in Japanese)","volume":"156","author":"Mori M","year":"2021","unstructured":"Mori M, Hidaka K. Pharmacological and clinical profile of gilteritinib (Xospata(\u00ae) tablets 40\u2005mg), a therapeutic agent for relapsed or refractory FLT3-mutated acute myeloid leukemia (Article in Japanese). Nihon Yakurigaku Zasshi. 2021, 156:37-46. 10.1254\/fpj.20050","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl AE","year":"2022","unstructured":"Perl AE, Larson RA, Podoltsev NA, et al.. Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022, 139:3366-75. 10.1182\/blood.2021011583","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMx220003","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"386","author":"Perl AE","year":"2022","unstructured":"Perl AE, Martinelli G, Cortes JE, et al.. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2022, 386:1868. 10.1056\/NEJMx220003","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v128.22.1069.1069","article-title":"Final results of the chrysalis trial: a first-in-human phase 1\/2 dose-escalation, dose-expansion study of gilteritinib (ASP2215) in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"128","author":"Perl AE","year":"2016","unstructured":"Perl AE, Altman JK, Cortes JE, et al.. Final results of the chrysalis trial: a first-in-human phase 1\/2 dose-escalation, dose-expansion study of gilteritinib (ASP2215) in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML). Blood. 2016, 128:1069-10. 10.1182\/blood.v128.22.1069.1069","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2006.01.006","article-title":"G-protein-coupled receptors and tyrosine kinases: crossroads in cell signaling and regulation","volume":"17","author":"Gavi S","year":"2006","unstructured":"Gavi S, Shumay E, Wang HY, Malbon CC. G-protein-coupled receptors and tyrosine kinases: crossroads in cell signaling and regulation. Trends Endocrinol Metab. 2006, 17:48-54. 10.1016\/j.tem.2006.01.006","journal-title":"Trends Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-10-0082","article-title":"Endocrine side effects of broad-acting kinase inhibitors","volume":"17","author":"Lodish MB","year":"2010","unstructured":"Lodish MB, Stratakis CA. Endocrine side effects of broad-acting kinase inhibitors. Endocr Relat Cancer. 2010, 17:R233-44. 10.1677\/ERC-10-0082","journal-title":"Endocr Relat Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ18-0491","article-title":"Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells","volume":"66","author":"Asari Y","year":"2019","unstructured":"Asari Y, Kageyama K, Sugiyama A, Kogawa H, Niioka K, Daimon M. Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells. Endocr J. 2019, 66:515-22. 10.1507\/endocrj.EJ18-0491","journal-title":"Endocr J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"Mori M","year":"2017","unstructured":"Mori M, Kaneko N, Ueno Y, et al.. Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017, 35:556-65. 10.1007\/s10637-017-0470-z","journal-title":"Invest New Drugs"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4271","article-title":"FDA approval summary: Gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation","volume":"27","author":"Pulte ED","year":"2021","unstructured":"Pulte ED, Norsworthy KJ, Wang Y, et al.. FDA approval summary: Gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Clin Cancer Res. 2021, 27:3515-21. 10.1158\/1078-0432.CCR-20-4271","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/276922-gilteritinib-induced-hypopituitarism-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T03:29:45Z","timestamp":1727580585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/276922-gilteritinib-induced-hypopituitarism-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.70401","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,28]]}}}